Skip to content
Clinical Trials – home
FranceBack to France

Clinical trials in Villeurbanne – page 134

2 127 clinical trials in Villeurbanne, France across 2 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

FranceOur site in FranceEssaisCliniques.fr(opens in a new tab)
Villeurbanne at a glance
2 127
clinical trials
  • Research sites2
Type of trial
Recruitment status
Quick filters

2 127 trials in Villeurbanne

Open in trial search

Study on the Effectiveness and Safety of Cyclophosphamide Monohydrate and Drug Combination for Patients with Persistent or Recurrent Rare Epithelial Ovarian Tumors

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Abemaciclib
  • Sponsor:F. Hoffmann-La Roche AG

Study of BDC-1001 and Pertuzumab for Patients with HER2-Positive Metastatic Breast Cancer Previously Treated with Trastuzumab Deruxtecan

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:BDC-1001
  • Sponsor:Bolt Biotherapeutics Inc.

Study on the Effectiveness and Safety of Remibrutinib Compared to Placebo and Omalizumab in Adults with Chronic Spontaneous Urticaria Uncontrolled by Antihistamines

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Omalizumab
  • Sponsor:Novartis Pharma AG

Study of Belumosudil and Prednisone for Patients Aged 12 and Older with Newly Diagnosed Chronic Graft Versus Host Disease

Registered drug
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Abiraterone Acetate
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Study of Tisotumab Vedotin, Pembrolizumab, and Platinum Drug Combination for Patients with Advanced or Metastatic Solid Tumors

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Seagen Inc.

Study on Alectinib and Durvalumab for Patients with Locally Advanced, Unresectable Stage III Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Alectinib
  • Sponsor:F. Hoffmann-La Roche AG

Plasma cell myeloma

Not recruiting

Study Comparing Talquetamab, Pomalidomide, and Teclistamab for Patients with Relapsed or Refractory Myeloma After 1 to 4 Prior Treatments

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Bortezomib
  • Sponsor:Janssen Cilag International

Malignant melanoma

Not recruiting

Study on the Safety and Effectiveness of Pembrolizumab and Drug Combination for Patients with Stage III Melanoma Eligible for Neoadjuvant Therapy

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Favezelimab
  • Sponsor:Merck Sharp & Dohme LLC

Breast cancer+3

Not recruiting

Study of Capivasertib and Fulvestrant for Patients with Advanced or Metastatic HR+/HER2- Breast Cancer

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Capivasertib
  • Sponsor:AstraZeneca AB

Study on the Effects of RGX-314 Gene Therapy Compared to Aflibercept and Ranibizumab for Patients with Neovascular Age-Related Macular Degeneration

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Aflibercept
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Study Comparing Entrectinib and Crizotinib for Patients with Advanced Non-Small Cell Lung Cancer with ROS1 Gene Changes, With or Without Brain Metastases

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Crizotinib
  • Sponsor:F. Hoffmann-La Roche AG

Malignant melanoma

Not recruiting

Study on the Safety and Effectiveness of Pembrolizumab and Tretinoin in Patients with PD-1 Refractory Melanoma

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Favezelimab
  • Sponsor:Merck Sharp & Dohme LLC

Other cities in France

The busiest research cities in the country

All 376 cities in France

Clinical research in Villeurbanne

What the registry says about research in the country

01 Neurodegenerative Diseases

Extensive research focusing on Alzheimer's disease treatments, including multiple studies evaluating novel therapeutic approaches for early-stage patients. Additional investigations examine Parkinson's disease and serotonergic receptor expression.

  • Early Alzheimer's Disease Interventions
  • Parkinson's Disease Mechanisms
  • Cognitive Function Assessment

Studies utilize innovative compounds and treatment strategies to address disease progression and symptoms.

02 Cardiovascular Health

Innovative research targeting heart failure prevention through combination therapy approaches. Studies evaluate new treatment strategies for reducing cardiovascular risks and improving patient outcomes.

  • Heart Failure Prevention
  • Cardiovascular Risk Management
  • Combined Therapeutic Approaches

Focus on preventive strategies and risk reduction in high-risk populations.

03 Oncology Research

Comprehensive studies in various cancer types, including colorectal cancer, breast cancer, and gastric cancer. Research emphasizes personalized treatment approaches and innovative therapeutic strategies.

  • Colorectal Cancer Treatment
  • Breast Cancer Hormone Therapy
  • Gastrointestinal Oncology

Trials incorporate advanced diagnostic methods and targeted therapies.

04 Respiratory Medicine

Studies examining treatments for severe asthma and COPD, evaluating new therapeutic combinations and investigating treatment responses in respiratory conditions.

  • Asthma Management
  • COPD Interventions
  • Respiratory Treatment Optimization

Focus on improving pulmonary outcomes and patient quality of life.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.